|
KMID : 1142020230580000011
|
|
Blood Research
2023 Volume.58 No. 0 p.11 ~ p.12
|
|
|
Practical issues in CAR T-cell therapy
|
|
Byun Ja-Min
|
|
|
Abstract
|
|
|
|
Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.
|
|
|
KEYWORD
|
|
|
CAR T-cell therapy, Korea, Patient access, Barrier
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|